Medindia LOGIN REGISTER
Medindia
Advertisement

Flurizan's Effect in Delaying Progression From Mild Cognitive Impairment to Alzheimer's Disease is Superior to That of Aricept

Wednesday, February 6, 2008 General News
Advertisement
WALTHAM, Mass., Feb. 5 Decision Resources, one of theworld's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, finds that a drug's effect on delaying the progression frommild cognitive impairment to Alzheimer's disease is the attribute that mostinfluences neurologists' prescribing decisions in the treatment of mildcognitive impairment. Clinical trial data and expert opinion shows that MyriadGenetics' Flurizan has advantages in this attribute over Eisai/Pfizer'sAricept/Bracco's Memac, the current sales leader and gold standard therapy formild cognitive impairment.
Advertisement

The new report entitled Mild Cognitive Impairment: An Off-Label Marketwith Significant Unmet Need and High Prevalence Carries SubstantialOpportunity finds that, following its launch in 2010, Flurizan will replaceAricept as the gold standard for mild cognitive impairment. Surveyed U.S.neurologists indicate that they would prescribe Flurizan to 20% of theirpatients with mild cognitive impairment and the report forecasts that Flurizanwill earn a 23% patient share in the U.S. market in 2016.
Advertisement

"Clinical trial data suggests that Flurizan has disease-modifyingproperties, an asset that interviewed experts expect will make the drug moreeffective at delaying the onset of Alzheimer's disease than currentlyavailable drugs," said Bethany Kiernan, Ph.D., analyst at Decision Resources."Flurizan's safety and tolerability profile is also better than other emergingcompetitors, and this, along with its efficacy, will make it the gold standardin the treatment of mild cognitive impairment in 2016."

About the Report

Mild Cognitive Impairment: An Off-Label Market with Significant Unmet Needand High Prevalence Carries Substantial Opportunity is a DecisionBase 2008report from Decision Resources. DecisionBase 2008 combines market forecastswith clinical and commercial end points to assess market share projections in35 indications. These outputs are driven by quantitative and qualitativeprimary research. DecisionBase 2008 provides detailed market share, patientshare, and price-per-day projections for emerging drugs in development. Themarket share projections are based on prescriber surveys that comparephysicians' expectations of a potential target product profile with anemerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members ofthe media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (www.decisionresources.com) is a world leader inmarket research publications, advisory services, and consulting designed tohelp clients shape strategy, allocate resources, and master their chosenmarkets. Decision Resources is a Decision Resources, Inc. company.All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders. For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 [email protected]

SOURCE Decision Resources
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close